Physician profile
Nick Ramandi
NPI 1124219050
$7,883.29
in general payments reported to CMS, 2019-2025
16 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,065 · 2020: $224 · 2021: $936 · 2022: $765 · 2023: $911 · 2024: $2,062 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,893.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,680.69 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $1,111.84 | 2019-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,073.76 | 2020-2025 | Caplyta |
| Alkermes, INC. | $759.69 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $617.87 | 2021-2025 | |
| Axsome Therapeutics, INC. | $536.91 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $441.56 | 2022-2025 | Uzedy, Austedo Xr |
| Jazz Pharmaceuticals INC. | $346.97 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.27 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $300.07 | 2019-2023 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $215.10 | 2025 | Cobenfy |
| Allergan, INC. | $125.00 | 2019 | |
| Collegium Pharmaceutical, INC. | $125.00 | 2025 | Jornay Pm |
| Uswm, LLC | $106.75 | 2024 | |
| Avanir Pharmaceuticals, INC. | $104.16 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $17.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Ramandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.